Clinical Trial Update: Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating clofarabine plus low-dose cytarabine in higher-risk myelodysplastic syndromes has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Syndromes
• Myeloproliferative Neoplasms

Drugs mentioned

• Clolar (Clofarabine)
• Cytarabine (Cytosar-U) (cytarabine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia, Myeloproliferative Diseases | Phase 2 | Status: COMPLETED | Results posted: 2018-05-31